Condition: Gastric Type Adenocarcinoma (GAS) With STK11 Mutation · Sponsor: Shanghai Jiatan Pharmatech Co., Ltd
The goal of this clinical trial is to evaluate the safety and preliminary efficacy of WX390 combined with Toripalimab in patients with advanced Gastric-type Endocervical Adenocarcinoma with STK11 mutations. The main questions it aims to answer are: * Pharmacokinetic (PK) characteristics of WX390 combined with Toripalimab treatment. * Safety and preliminary in combined therapy. Participants will be treated with WX390 orally and Toripalimab intravenously, and follow the efficacy and safety evaluation according to the protocol.
This description comes directly from the study's public registry record.
Gaoli He · 008621-63453967 · fcklcsyjg@163.com
Always discuss trial participation with your own doctor first.
| The Obstetrics & Gynecology Hospital of Fudan University (Shanghai Red House Ob & Gyn Hospital) | Shanghai, Shanghai Municipality, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06124963